Literature DB >> 7758239

Two cases of Wegener's granulomatosis involving the pituitary.

G A Roberts1, E Eren, H Sinclair, M Pelling, A Burns, R Bradford, R Maurice-Williams, C M Black, N Finer, P M Bouloux.   

Abstract

We describe two patients with Wegener's granulomatosis involving the pituitary. The diagnosis of Wegener's granulomatosis was inferred from the histological appearance of biopsy tissue and the presence of anti-neutrophil cytoplasmic antibodies with cytoplasmic distribution in the first case, in which disease remained confined to the pituitary, causing anterior and posterior pituitary dysfunction. In the second case the diagnosis was made by the progressive involvement of other organ systems, compatible histology and the presence of anti-neutrophil cytoplasmic antibodies with cytoplasmic distribution. In neither patient did posterior pituitary dysfunction respond to immunosuppressive therapy, despite remission of other features of systemic vasculitis. Panhypopituitarism in association with isolated pituitary Wegener's granulomatosis has not previously been described.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7758239     DOI: 10.1111/j.1365-2265.1995.tb01882.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  13 in total

1.  Wegener granulomatosis causing sellar mass, hydrocephalus, and global pituitary failure.

Authors:  R D Bertken; V R Cooper
Journal:  West J Med       Date:  1997-07

2.  A diagnostic pitfall in IgG4-related hypophysitis: infiltration of IgG4-positive cells in the pituitary of granulomatosis with polyangiitis.

Authors:  Hironori Bando; Genzo Iguchi; Hidenori Fukuoka; Masaaki Taniguchi; Seiji Kawano; Miki Saitoh; Kenichi Yoshida; Ryusaku Matsumoto; Kentaro Suda; Hitoshi Nishizawa; Michiko Takahashi; Akio Morinobu; Eiji Kohmura; Wataru Ogawa; Yutaka Takahashi
Journal:  Pituitary       Date:  2015-10       Impact factor: 4.107

Review 3.  Pituitary involvement in patients with granulomatosis with polyangiitis: case series and literature review.

Authors:  Yu Gu; Xuefeng Sun; Min Peng; Ting Zhang; Juhong Shi; Jiangfeng Mao
Journal:  Rheumatol Int       Date:  2019-06-15       Impact factor: 2.631

4.  Granulomatous hypophysitis due to Wegener's granulomatosis.

Authors:  M Goyal; W Kucharczyk; E Keystone
Journal:  AJNR Am J Neuroradiol       Date:  2000-09       Impact factor: 3.825

Review 5.  Pituitary involvement in Wegener's granulomatosis.

Authors:  Tuck Y Yong; Jordan Y Z Li; Lisa Amato; Kumar Mahadevan; Patrick J Phillips; Penelope S Coates; P Toby H Coates
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

6.  Pituitary adenoma with tumoral granulomatous reaction.

Authors:  Bernd W Scheithauer; Ana Isabel Silva; John L D Atkinson; Todd B Nippoldt; Timothy J Kaufmann; Kalman Kovacs; Eva Horvath; Ricardo Lloyd
Journal:  Endocr Pathol       Date:  2007       Impact factor: 3.943

7.  Pituitary granulomatosis with polyangiitis.

Authors:  Hannah Slabu; Terra Arnason
Journal:  BMJ Case Rep       Date:  2013-05-03

8.  Pituitary involvement in granulomatosis with polyangiitis: report of 9 patients and review of the literature.

Authors:  Audrey De Parisot; Xavier Puéchal; Corinne Langrand; Gerald Raverot; Helder Gil; Laurent Perard; Guillaume Le Guenno; Sabine Berthier; Olivier Tschirret; Jean Paul Eschard; Stephane Vinzio; Loïc Guillevin; Pascal Sève
Journal:  Medicine (Baltimore)       Date:  2015-04       Impact factor: 1.889

9.  Diabetes insipidus as a complication of Wegener's granulomatosis and its treatment with biologic agents.

Authors:  Joanna Rosalind Cunnington; Ramesh Jois; Ivan Zammit; David Scott; John Isaacs
Journal:  Int J Rheumatol       Date:  2009-07-26

Review 10.  Severe localised granulomatosis with polyangiitis (Wegener's granulomatosis) manifesting with extensive cranial nerve palsies and cranial diabetes insipidus: a case report and literature review.

Authors:  James E Peters; Vivek Gupta; Ibtisam T Saeed; Curtis Offiah; Ali S M Jawad
Journal:  BMC Neurol       Date:  2018-05-01       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.